The estimated Net Worth of Richard Chesworth is at least $1.96 million dollars as of 27 August 2021. Dr Chesworth owns over 33,779 units of Kymera Therapeutics stock worth over $1,512,286 and over the last 4 years he sold KYMR stock worth over $0. In addition, he makes $447,875 as Chief Scientific Officer at Kymera Therapeutics.
Sign up
Dr D KYMR stock SEC Form 4 insiders trading
Dr has made over 2 trades of the Kymera Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 33,779 units of KYMR stock worth $675,580 on 27 August 2021.
The largest trade he's ever made was exercising 54,000 units of Kymera Therapeutics stock on 17 August 2021 worth over $1,080,000. On average, Dr trades about 21,945 units every 3 days since 2020. As of 27 August 2021 he still owns at least 33,779 units of Kymera Therapeutics stock.
You can see the complete history of Dr Chesworth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Richard Chesworth Ph.D. biography
Dr. Richard Chesworth Ph.D. is the Chief Scientific Officer at Kymera Therapeutics.
What is the salary of Dr D?
As the Chief Scientific Officer of Kymera Therapeutics, the total compensation of Dr D at Kymera Therapeutics is $447,875. There are 2 executives at Kymera Therapeutics getting paid more, with Dr. Nello Mainolfi M.D., Ph.D. having the highest compensation of $832,619.
How old is Dr D?
Dr D is 50, he's been the Chief Scientific Officer of Kymera Therapeutics since . There are 2 older and 4 younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics, Inc. is Dr. Jared A. Gollob, 57, who is the Chief Medical Officer.
What's Dr D's mailing address?
Richard's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN, MA, 02472.
Insiders trading at Kymera Therapeutics
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B... et Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
What does Kymera Therapeutics do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
What does Kymera Therapeutics's logo look like?
Complete history of Dr Chesworth stock trades at Kymera Therapeutics
Kymera Therapeutics executives and stock owners
Kymera Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Nello Mainolfi M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Dr. Jared A. Gollob,
Chief Medical Officer -
Dr. Richard Chesworth Ph.D.,
Chief Scientific Officer -
Dr. Bruce L. Booth D.Phil., Ph.D.,
Co-Founder & Chairman -
Dr. Bruce L. Booth Ph.D., D.Phil.,
Co-Founder & Chairman -
Dr. Mark E. Nuttall Ph.D.,
Chief Bus. Officer -
Tyler Gagnon,
Director of Corp. Communications -
Vijay Sabesan,
Sr. VP of Technical Operations -
Paige Cochran,
VP of HR -
Karen Martin J.D., Ph.D.,
VP & Head of Legal -
Paul Cox,
VP of Investor Relations & Communications -
Michael J. Todisco,
VP of Accounting & Fin. -
Brian Albarran M.B.A., Ph.D.,
VP of Strategy & Operations -
Bruce N. Jacobs CFA,
Chief Financial Officer -
Bruce N. Jacobs,
Chief Financial Officer -
Venture Fund X, L.P. Atlas,
10% owner -
Venture Fund X, L.P.Atlas V...,
-
Group, Llc Green Jeremy Red...,
-
Partners L P/Ilbiotechnolog...,
-
Biomedical Innovation Maste...,
10% owner -
Elena Ridloff,
-
Venture Associates X, L.P.A...,
-
Elaine Caughey,
Chief Business Officer -
Bros. Advisors Lp667, L.P.B...,
-
Jeffrey W. Albers,
-
Richard Chesworth,
Chief Scientific Officer -
Donald William Nicholson,
Director -
Bruce Booth,
-
Andrew Hedin,
Director -
Steven Edward Hall,
Director -
John Maraganore,
-
Venture Fund X, L.P.Atlas V...,
-
Pamela Esposito,
-
Leigh Morgan,
-
Gorjan Hrustanovic,
-
Victor Sandor,
-
Ellen Chiniara,
Chief Legal Officer -
Jeremy G Chadwick,
Chief Operating Officer -
Nello Mainolfi,
Chief Executive Officer -
Jared Gollob,
Chief Medical Officer -
Joanna Horobin,